Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4352026 | 0.88 | S1PR5 (0.49) | NPC1RAB9AMEN1KMT2AS1PR5 | |
| SCHEMBL4346924 | 0.87 | GRIN1 (0.43) | MEN1KMT2AS1PR5S1PR1ALDH1A1 | |
| SCHEMBL4353675 | 0.86 | RORC (0.44) | S1PR5 | |
| SCHEMBL4345654 | 0.85 | RORC (0.43) | S1PR5 | |
| SCHEMBL4349396 | 0.84 | PRKAA2 (0.45) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL4348326 | 0.83 | KCNH2 (0.50) | — | |
| SCHEMBL4351876 | 0.83 | FAAH (0.45) | ALDH1A1KDM4ELMNAHTT | |
| SCHEMBL4352087 | 0.82 | DRD4 (0.39) | RAB9AMEN1KMT2AS1PR5S1PR1 | |
| SCHEMBL4533849 | 0.82 | MCHR1 (0.42) | — | |
| SCHEMBL4350062 | 0.82 | PTPN1 (0.45) | S1PR5S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010485-B1 | AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS | PROSIDION LTD (GB) | 2012-10-17 | — | — | EP | claimed |
| US-20090281076-A1 | Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists | PROSIDION LIMITED (GB) | 2009-11-12 | — | — | US | claimed |
| EP-2010485-B1 | AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS | PROSIDION LTD (GB) | 2012-10-17 | — | — | EP | disclosed |
| US-20090281076-A1 | Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists | PROSIDION LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090281076-A1 | Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists | PROSIDION LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| WO-2007116230-A1 | AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS | PROSIDION LTD (GB) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281076-A1 | Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists | GPR119, GPR39, GIPR | NPC1 1056/4885RAB9A 297/4885MEN1 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.